Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Primary CNS Lymphoma (PCNSL)Diffuse Large B Cell Lymphoma (DLBCL)
Interventions
GENETIC

Anbal-cel

"On Day 1 (D1), Anbal-cel will be administered only to subjects who meet the final inclusion/exclusion criteria for Anbal-cel administration before the infusion.~As premedication before Anbal-cel administration, acetaminophen or paracetamol, and diphenhydramine or H1 antihistamine will be given.~Anbal-cel will be administered as a single intravenous infusion on Day 1 within 30 minutes of thawing, at the dose presented in the following table:~Dose: 2x10\^6 (CAR-T cells/kg)\* Maximum 2 x 10\^8 cells"

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Asan Medical Center

OTHER

lead

Hyungwoo Cho

OTHER

NCT07062627 - Anbalcabtagene Autoleucel in Relapsed/Refractory CNS Lymphoma | Biotech Hunter | Biotech Hunter